Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...
Gene therapy
Kactus Biosystems and Levinthal Biotech Deepen Strategic Partnership
Kactus Biosystems, a Shanghai-based firm specializing in target proteins and raw enzymes, has announced a...
Chinagene Tech Initiates ZVS101e Gene Therapy Trial for Bietti’s Crystalline Dystrophy
Beijing-based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has announced the...
BRL Medicine Achieves First Cure of Thalassemia Major with BRL-101
Shanghai-based BRL Medicine Inc. has announced a significant breakthrough in the treatment of thalassemia major....
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...
BDgene’s CRISPR-Cas9 Therapy BD111 Accepted for CDE Review
Shanghai BDgene Technology Co., Ltd has announced that a clinical trial filing for its BD111,...
NeuShen Therapeutics Partners with UMass Chan for ALS Gene Therapy Development
Sino-US biotech firm NeuShen Therapeutics Inc., focused on central nervous system (CNS) disorders, has announced...
R&B Bio Raises RMB 200 Million in Series A+ Round to Advance Gene Therapy Pipeline
Chengdu-based gene therapy firm R&B Biotech has reportedly secured over RMB 200 million (USD 29.64...
Exegenesis Bio Gains FDA Approval for Gene Therapy EXG102-031 in Wet AMD
Hangzhou-based clinical stage gene therapy firm Exegenesis Bio has announced receiving approval from the US...
China Updates Export Controls on Technologies, Adds Gene Editing to List
The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted...
HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...
Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines
Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly...
CANbridge Secures Global Rights to Second-Generation Gene Therapy for SMA
China – based biopharma CANbridge Pharmaceuticals Inc. (HKG: 1228) has unveiled a license deal to...
Chinagene Tech’s ZVS101e Receives FDA IND Approval for Bietti’s Crystalline Dystrophy
Beijing – based Chinagene Tech, a specialist in hereditary ophthalmopathy diagnosis and gene therapy, has...
Neurophth Partners with Apellis for Gene Therapy Development in AMD
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with US firm...
Waker Bioscience Raises Angel Funding for ISA Technology Upgrades
Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens...
Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment
China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval...
GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development
China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised...
ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy
Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...